1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | MDA_MB_436; MDA MB 436; MDA-Mb-436; MDA-MB436; MDAMB436; MDA-436; MDA436; MB436; MD Anderson-Metastatic Breast-436 |
| Species | Human |
| Cat.No | ABC-TC0655 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃ |
| Source Organ | Breast |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
MDA-MB-436 is a triple-negative breast cancer (TNBC) cell line derived from the pleural effusion of a patient with breast adenocarcinoma. The splice donor site of exon 20 in MDA-MB-436 cell line harbored the 5396 + 1G>A mutation, which is accompanied by the loss of the remaining BRCA1 allele. MDA-MB-436 is characterized as a claudin-low TNBC cell line that exhibits a mesenchymal-cell-like morphology. MDA-MB-436 exhibits pleomorphism, and a significant proportion of the cells show strong reactivity when subjected to indirect immunofluorescence staining using an anti-tubulin antibody. MDA-MB-436 can be cultured in Leibovitz’s L-15 medium with 10% FBS.
Why choose MDA-MB-436 from AcceGen?
MDA-MB-436 from AcceGen has high standards of sterility, negative for contamination from bacterial, fungal, and mycoplasma sources (confirmed through PCR analysis). The post-thaw viability of MDA-MB-436 exceeds 95%, indicating excellent preservation and functionality even after cryopreservation. This high viability rate is crucial for reliable and robust experimental results. The growth characteristics of MDA-MB-436 are evaluated based on their morphology and immunocytochemistry of multiple undifferentiation markers. Overall, AcceGen performed comprehensive assessments to ensure its reliability for scientific uses.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
MDA-MB-436 can be used as a model to identify the effect of novel drugs or existing agents on breast cancer patients, and identify growth factors in the tumor growth and potential targets for a novel therapeutic strategy for TNBCs. It’s interesting that retinoic acid(RA), an existing anti-cancer agent, decreases the tumor growth of basal-like TNBC cell line (such as MDA-MB-468) but increases the tumor growth of claudin-low TNBC (such as MDA-MB-231, MDA-MB-436). The following investigation may be the determination of key factors in the pathway of RA to further understand the difference between basal-like and claudin-low TNBC, and also benefit to diagnose the type of breast cancer and speculate the response of patient tumors to a novel therapeutic strategy.
